<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CALCIUM CHLORIDE</span><br/><span class="topboxtradename">Calciject, </span><span class="topboxtradename">Calcitrans, </span><span class="topboxtradename">Solucalcine<br/></span><b>Classifications:</b> <span class="classification">fluid and electrolytic balance agent</span>; <span class="classification">replacement solution</span><br/><b>Prototype: </b>Calcium gluconate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10% injection</p>
<h1><a name="action">Actions</a></h1>
<p>Actions similar to those of calcium gluconate. Ionizes more readily and thus is more potent than calcium gluconate and more
         irritating to tissues. Provides excess chloride ions that promote acidosis and temporary (12 d) diuresis secondary to
         excretion of sodium.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Rapidly and effectively restores serum calcium levels in acute hypocalcemia of various origins and an effective cardiac stabilizer
         under conditions of hyperkalemia or resuscitation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of cardiac resuscitation when epinephrine fails to improve myocardial contractions; for treatment of acute hypocalcemia
         (as in tetany due to parathyroid deficiency, vitamin D deficiency, alkalosis, insect bites or stings, and during exchange
         transfusions), for treatment of hypermagnesemia, and for cardiac disturbances of hyperkalemia.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Ventricular fibrillation, hypercalcemia, digitalis toxicity, injection into myocardium or other tissue; pregnancy (category
         C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Digitalized patients; sarcoidosis, renal insufficiency, history of renal stone formation; cor pulmonale, respiratory acidosis,
         respiratory failure; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td>
<p>
<b>All doses are in terms of <i>elemental calcium:</i> 1 g calcium chloride = 272 mg (13.6 mEq) elemental calcium</b>
</p><span class="indicationtitle">Hypocalcemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.51 g (714 mEq) at 13 d intervals as determined by patient response and serum calcium levels<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 25 mg/kg (17 mEq) administered slowly<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> <br/><span class="indicationtitle">Hypocalcemic Tetany</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 4.516 mEq prn<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.50.7 mEq/kg t.i.d. or q.i.d.<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 2.4 mEq/kg/d in divided doses<br/><br/><span class="indicationtitle">CPR</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 2.73.7 mEq <small>x</small> 1<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 20 mg/kg, may repeat in 10 min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to neonates, infants, and children: Verify correct IV concentration and rate of infusion with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> May be given undiluted or diluted (preferred) with an equal volume of NS for injection. Solution should be warmed to body
                  temperature before administration.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at 0.51 mL/min or more slowly if irritation develops. Avoid rapid administration. Use a small-bore needle and inject
                  into a large vein to minimize venous irritation and undesirable reactions  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Amphotericin B,</b>
<b>chlopheniramine,</b>
<b>dobutamine,</b> concentration-dependent incompatibility with other <span class="classification">electrolytes.</span>
<span class="incompattype">Y-site:</span>
<b>Amphotericin B cholesteryl complex,</b>
<b>propofol,</b>
<b>sodium bicarbonate</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Tingling sensation. With rapid IV, sensations of heat waves (peripheral vasodilation), fainting, <span class="typehead">CV:</span> (With rapid infusion) hypotension, bradycardia, cardiac arrhythmias, <span class="speceff-life">cardiac arrest</span>. <span class="typehead">Skin:</span> Pain and burning at IV site, severe venous thrombosis, necrosis and sloughing (with extravasation). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>  May enhance inotropic and toxic effects of <b>digoxin;</b> antagonizes the effects of <b>verapamil</b> and possibly other <span class="classification">calcium channel blockers</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Elimination:</span> Primarily excreted in feces; small amounts excreted in urine, pancreatic juice, saliva, and breast milk. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor ECG and BP and observe patient closely during administration. IV injection may be accompanied by cutaneous burning
            sensation and peripheral vasodilation, with moderate fall in BP.
         </li>
<li>Advise ambulatory patient to remain in bed for 1530 min or more depending on response following injection.</li>
<li>Observe digitalized patients closely since an increase in serum calcium increases risk of digitalis toxicity.</li>
<li>Lab tests: Determine serum pH, calcium, and other electrolytes frequently as guides to dosage adjustments.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Remain in bed for 1530 min or more following injection and depending on response.</li>
<li>Symptoms of mild hypercalcemia, such as loss of appetite, nausea, vomiting, or constipation may occur. If hypercalcemia becomes
            severe, call health care provider if feeling confused or extremely excited.
         </li>
<li>Do not use other calcium supplements or eat foods high in calcium, like milk, cheese, yogurt, eggs, meats, and some cereals,
            during therapy.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>